Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma

por Meniawy, T M, Creaney, J, Lake, R A, Nowak, A K
Publicado 2013

Response to comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'

por Meniawy, T M, Creaney, J, Lake, R A, Nowak, A K
Publicado 2014

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies

por McCoy, M J, Lake, R A, van der Most, R G, Dick, I M, Nowak, A K
Publicado 2012

p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression

por Creaney, J, McLaren, B M, Stevenson, S, Musk, A W, Klerk, N de, Robinson, B W S, Lake, R A
Publicado 2001

A Subset of Malignant Mesothelioma Tumors Retain Osteogenic Potential

por Lansley, S. M., Pedersen, B., Robinson, C., Searles, R. G., Sterrett, G., van Bruggen, I., Lake, R. A., Mutsaers, S. E., Prêle, C. M.
Publicado 2016

Low stromal Foxp3(+) regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer

por McCoy, M J, Hemmings, C, Miller, T J, Austin, S J, Bulsara, M K, Zeps, N, Nowak, A K, Lake, R A, Platell, C F
Publicado 2015